Bal Pharma Limited (BALPHARMA) - Total Liabilities
Based on the latest financial reports, Bal Pharma Limited (BALPHARMA) has total liabilities worth Rs2.93 Billion INR (≈ $31.72 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore BALPHARMA net asset momentum to track the company's year-over-year net asset growth rate.
Bal Pharma Limited - Total Liabilities Trend (2006–2026)
This chart illustrates how Bal Pharma Limited's total liabilities have evolved over time, based on quarterly financial data. See BALPHARMA FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Bal Pharma Limited Competitors by Total Liabilities
The table below lists competitors of Bal Pharma Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Kodi-S Co Ltd
KQ:080530
|
Korea | ₩24.56 Billion |
|
The Western India Plywoods Limited
NSE:WIPL
|
India | Rs373.40 Million |
|
CSLM Acquisition Corp.
NASDAQ:CSLMF
|
USA | $11.70 Million |
|
Keynote Financial Services Limited
NSE:KEYFINSERV
|
India | Rs114.13 Million |
|
Avrasya Petrol ve Turistik Tesisler Yatirimlar AS
IS:AVTUR
|
Turkey | TL197.96 Million |
|
Waja Konsortium Bhd
KLSE:0102
|
Malaysia | RM17.98 Million |
|
Shinpoong Pharmaceutical Co Ltd
KO:019175
|
Korea | ₩79.62 Billion |
|
LL Lucky Games publ AB
ST:LADYLU
|
Sweden | Skr35.38 Million |
Liability Composition Analysis (2006–2026)
This chart breaks down Bal Pharma Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Bal Pharma Limited market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.05 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.57 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.78 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bal Pharma Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bal Pharma Limited (2006–2026)
The table below shows the annual total liabilities of Bal Pharma Limited from 2006 to 2026.
| Year | Total Liabilities | Change |
|---|---|---|
| 2026-03-31 | Rs2.93 Billion ≈ $31.72 Million |
+13.55% |
| 2025-03-31 | Rs2.58 Billion ≈ $27.93 Million |
+3.21% |
| 2024-03-31 | Rs2.50 Billion ≈ $27.07 Million |
+0.32% |
| 2023-03-31 | Rs2.49 Billion ≈ $26.98 Million |
+23.48% |
| 2022-03-31 | Rs2.02 Billion ≈ $21.85 Million |
+8.20% |
| 2021-03-31 | Rs1.87 Billion ≈ $20.19 Million |
-3.28% |
| 2020-03-31 | Rs1.93 Billion ≈ $20.88 Million |
-4.00% |
| 2019-03-31 | Rs2.01 Billion ≈ $21.75 Million |
+4.94% |
| 2018-03-31 | Rs1.92 Billion ≈ $20.72 Million |
+12.59% |
| 2017-03-31 | Rs1.70 Billion ≈ $18.41 Million |
+8.88% |
| 2016-03-31 | Rs1.56 Billion ≈ $16.90 Million |
+43.80% |
| 2015-03-31 | Rs1.09 Billion ≈ $11.75 Million |
+3.82% |
| 2014-03-31 | Rs1.05 Billion ≈ $11.32 Million |
-0.50% |
| 2013-03-31 | Rs1.05 Billion ≈ $11.38 Million |
+4.07% |
| 2012-03-31 | Rs1.01 Billion ≈ $10.93 Million |
+2.00% |
| 2011-03-31 | Rs991.28 Million ≈ $10.72 Million |
+12.09% |
| 2010-03-31 | Rs884.40 Million ≈ $9.56 Million |
+4.91% |
| 2009-03-31 | Rs843.01 Million ≈ $9.12 Million |
+14.22% |
| 2008-03-31 | Rs738.08 Million ≈ $7.98 Million |
+29.20% |
| 2007-03-31 | Rs571.26 Million ≈ $6.18 Million |
+2.38% |
| 2006-03-31 | Rs558.01 Million ≈ $6.03 Million |
-- |
About Bal Pharma Limited
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Az… Read more